Restoration of Sinus Rhythm in Patients With Persistent Atrial Fibrillation and Obesity: New Possibilities of Pharmacological Cardioversion
https://doi.org/10.18087/cardio.2017.10.10036
Abstract
We present in this article 2 cases of successful pharmacological restoration of sinus rhythm by a new class III antiarrhythmic drug refralon in patients with obesity and persistent atrial fibrillation. In both cases, the effective use of refralon was preceded by repeated ineffective attempts of electrical cardioversion. In the article we discuss the role of obesity as the factor leading to a substantial increase of transthoracic electrical resistance, and thus significantly reducing the probability of sinus rhythm restoration by means of electrical cardioversion. The clinical examples described in this article clearly show that the use of refralon may represent a unique clinical alternative to electrical cardioversion for sinus rhythm restoration in patients with persistent atrial fibrillation, and in some cases where the success of electrical cardioversion is obviously questionable, like in patients with severe obesity, the use of refralon seems preferable.
About the Authors
Vladislav V. Vlodzyanovskiy
Institute of Cardiology, Russian Cardiology Scientific and Production Complex
Russian Federation
Russian Federation
T. A. Malkina
Institute of Cardiology, Russian Cardiology Scientific and Production Complex
Russian Federation
Russian Federation
S. F. Sokolov
Institute of Cardiology, Russian Cardiology Scientific and Production Complex
Russian Federation
Russian Federation
M. A. Saidova
Institute of Cardiology, Russian Cardiology Scientific and Production Complex
Russian Federation
Russian Federation
S. P. Golitsyn
Institute of Cardiology, Russian Cardiology Scientific and Production Complex
Russian Federation
Russian Federation
L. V. Rozenshtraukh
Institute of Cardiology, Russian Cardiology Scientific and Production Complex
Russian Federation
Russian Federation
E. I. Chazov
Institute of Cardiology, Russian Cardiology Scientific and Production Complex
Russian Federation
Russian Federation
References
1. Artham S.M., Lavie C.J., Milani R.V., Ventura H.O. Obesity and hypertension, heart failure, and coronary heart disease-risk factor, paradox, and recommendations for weight loss. Ochsner J. 2009;9(3):124-132.
2. Alpert M.A. Obesity cardiomyopathy: pathophysiology and evolution of the clinical syndrome. Am J. Med Sci 2001;321(4):225-236.
3. Messerli F.H., Nunez B.D., Ventura H.O., Snyder D.W. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987;147(10):1725-1278.
4. Wang T.J., Parise H., Levy D., et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004;292(20):2471-2477.
5. Wanahita N., Messerli F. H., Bangalore S. et al. Atrial fibrillation and obesity - results of a meta-analysis. Am Heart J. 2008;155(2):310-315. doi: 10.1016/j.ahj.2007.10.004. Epub 2007 Dec 19.
6. Camm A.J., Kirchhof P., Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
7. Wann S., Curtis A. B., January C. T. et al. 2011 ACCF/AHA/ HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). A Report of the American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines. Circulation 2011;123:104-123.
8. Galperin J., Elizari M.V., Chiale P.A. et al. Pharmacologic reversion of persistent atrial fibrillation with amiodarone predicts longterm sinus rhythm maintenance J. Cardiovasc Pharmacol Ther 2003;8:179-186.
9. Roy D., Pratt C.M., Torp-Pedersen C. et al. for the Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebocontrolled trial Circulation 2008;117:518-1525.
10. Van Gelder I.C., Crijns H.J., Van Glist W.H. et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J. Cardiol 1991;68:41-46.
11. Rashba E., Bouhouch R., Koshy S. et al. A new algorithm for trans-thoracic cardioversion of atrial fibrillation based on body weight. Am J. Cardiol 2001;88:1043-1045.
12. Востриков В. А. Электроимпульсная терапия предсердных и желудочковых тахиаритмий. С. 245-272 в кн.: «Руководство по нарушениям ритма сердца». Под ред. Е. И. Чазова и С. П. Голицына. М: ГЭОТАР-Медиа 2008.
13. Юричева Ю. А., Майков Е. Б., Соколов С. Ф. и др. Первый опыт клинического применения нового антиаритмического препарата III класса ниферидила у больных с персистирующей формой фибрилляции предсердий. Кардиология 2011;1:55-64.
14. Юричева Ю. А., Соколов С. Ф., Голицын С. П. и др. Новый антиаритмический препарат III класса ниферидил, как эффективное средство восстановления синусового ритма при персистирующей форме мерцательной аритмии. Вестник аритмологии 2012;70:32-43.
15. Maron D.J., Towbin J.A., Thiene G. et al. Contemporary Definitions and Classification of the Cardiomyopathies: An American Heart Association Scientific Statement From the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 2006;113:1807-1816.
16. Fenelon G., Wijns W., Andries E., Brugada P. Tachycardiomyopathy: mechanisms and clinical applications. Pacing Clin Electrophysiol 1996;19:95-106.
17. Федеральное руководство по использованию лекарственных средств (формулярная система). Выпуск VII. Под ред. А. Г. Чучалина, В. В. Яснецова. М., 2016.
Review
For citations:
Vlodzyanovskiy V.V., Malkina T.A., Sokolov S.F., Saidova M.A., Golitsyn S.P., Rozenshtraukh L.V., Chazov E.I. Restoration of Sinus Rhythm in Patients With Persistent Atrial Fibrillation and Obesity: New Possibilities of Pharmacological Cardioversion. Kardiologiia. 2017;57(10):80-86. (In Russ.) https://doi.org/10.18087/cardio.2017.10.10036
Views:
1562
Email this article 
Post a Comment 
